EA
INSM icon

Ellsworth Advisors’s Insmed INSM Stock Holding History

Ellsworth Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,212
Closed -$469K – 187
2024
Q1 		$469K Buy
+17,212
New +$482K 0.13% 134

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Ellsworth Advisors's INSM Position: Q2 2024 in Review

Ellsworth Advisors sold out of Insmed (INSM) in Q2 2024, closing a stake of 17,212 shares — an estimated $469K sold.

Ellsworth Advisors first reported a position in INSM in Q1 2024 and held it in 1 quarter. The position peaked at $469K in Q1 2024. 378 funds tracked by Wall St. Rank hold INSM as of Q2 2024.

  • Ellsworth Advisors reported no remaining Insmed position as of Q2 2024 after selling out during the quarter.
  • Ellsworth Advisors sold 17,212 Insmed shares in Q2 2024, an estimated $469K.
  • Ellsworth Advisors first reported a position in Insmed in Q1 2024 and held it in 1 quarter.
  • Ellsworth Advisors's Insmed position peaked at $469K in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Insmed as of Q2 2024.

Based on Ellsworth Advisors's 13F filing for Q2 2024, filed 18 Jul 2024.